JP2023514568A5 - - Google Patents
Info
- Publication number
- JP2023514568A5 JP2023514568A5 JP2022548896A JP2022548896A JP2023514568A5 JP 2023514568 A5 JP2023514568 A5 JP 2023514568A5 JP 2022548896 A JP2022548896 A JP 2022548896A JP 2022548896 A JP2022548896 A JP 2022548896A JP 2023514568 A5 JP2023514568 A5 JP 2023514568A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- parp
- usp1
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976864P | 2020-02-14 | 2020-02-14 | |
| US62/976,864 | 2020-02-14 | ||
| US202063032245P | 2020-05-29 | 2020-05-29 | |
| US63/032,245 | 2020-05-29 | ||
| US202163146937P | 2021-02-08 | 2021-02-08 | |
| US63/146,937 | 2021-02-08 | ||
| PCT/US2021/017912 WO2021163530A1 (en) | 2020-02-14 | 2021-02-12 | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514568A JP2023514568A (ja) | 2023-04-06 |
| JP2023514568A5 true JP2023514568A5 (https=) | 2024-02-21 |
Family
ID=77291879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548896A Pending JP2023514568A (ja) | 2020-02-14 | 2021-02-12 | ユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤を含む治療効果のある組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230277533A1 (https=) |
| EP (1) | EP4103165A4 (https=) |
| JP (1) | JP2023514568A (https=) |
| KR (1) | KR20220140732A (https=) |
| CN (1) | CN115066235A (https=) |
| AU (1) | AU2021218805A1 (https=) |
| CA (1) | CA3168009A1 (https=) |
| IL (1) | IL295149A (https=) |
| MX (1) | MX2022009818A (https=) |
| TW (1) | TW202140026A (https=) |
| WO (1) | WO2021163530A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021163530A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| KR20230098186A (ko) | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
| US20240409538A1 (en) * | 2021-10-19 | 2024-12-12 | Impact Therapeutics (Shanghai), Inc. | Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof |
| IL312642A (en) * | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| EP4430049A4 (en) * | 2021-11-12 | 2025-12-17 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof |
| US20250161306A1 (en) * | 2022-01-25 | 2025-05-22 | KSQ Therapeutics, Inc. | Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors |
| JP2025531133A (ja) * | 2022-09-20 | 2025-09-19 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ユビキチン特異的プロテアーゼ阻害剤としてのカルボニル縮合複素環誘導体 |
| CA3268518A1 (en) * | 2022-09-23 | 2024-03-28 | KSQ Therapeutics, Inc. | THERAPEUTIC COMBINATIONS INCLUDING UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS (USP1) AND SELECTIVE PARP1 INHIBITORS |
| CN117384187B (zh) * | 2022-09-30 | 2026-01-30 | 轩竹生物科技股份有限公司 | 泛素特异性蛋白酶1抑制剂 |
| EP4605391A1 (en) | 2022-10-21 | 2025-08-27 | Exelixis, Inc. | 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| TW202509030A (zh) | 2023-05-08 | 2025-03-01 | 美商譚格醫療公司 | 化合物及使用方法 |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| CN121866064A (zh) * | 2023-06-16 | 2026-04-14 | 韩国科学技术研究院 | 包含BRCA特异性siRNA作为活性成分的用于预防或治疗靶向癌症的药物组合物 |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025087460A1 (zh) * | 2023-10-25 | 2025-05-01 | 海思科医药集团股份有限公司 | 一种吡啶并吡唑衍生物药物组合物及其应用 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| TW202539659A (zh) | 2024-01-10 | 2025-10-16 | 美商維瑞斯治療股份有限公司 | Ｄｎａ損傷修復途徑的新穎抑制劑 |
| WO2025153067A1 (zh) * | 2024-01-19 | 2025-07-24 | 江苏亚虹医药科技股份有限公司 | Usp1抑制剂及其医药用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025180502A1 (zh) * | 2024-03-01 | 2025-09-04 | 上海齐鲁制药研究中心有限公司 | 一种联合用药物组合物及其用途 |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2797719C (en) * | 2010-04-30 | 2019-11-26 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of usp1 deubiquitinating enzyme activity |
| GB201519573D0 (en) * | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| WO2018165615A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
| KR20190130625A (ko) * | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| US11485736B2 (en) * | 2018-12-20 | 2022-11-01 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| US20230065636A1 (en) * | 2020-01-15 | 2023-03-02 | KSQ Therapeutics, Inc. | Compositions of substituted pyrazolopyrimidines and uses thereof |
| WO2021163530A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| KR20230098186A (ko) * | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
-
2021
- 2021-02-12 WO PCT/US2021/017912 patent/WO2021163530A1/en not_active Ceased
- 2021-02-12 MX MX2022009818A patent/MX2022009818A/es unknown
- 2021-02-12 US US17/904,159 patent/US20230277533A1/en not_active Abandoned
- 2021-02-12 KR KR1020227027461A patent/KR20220140732A/ko active Pending
- 2021-02-12 CA CA3168009A patent/CA3168009A1/en active Pending
- 2021-02-12 JP JP2022548896A patent/JP2023514568A/ja active Pending
- 2021-02-12 AU AU2021218805A patent/AU2021218805A1/en active Pending
- 2021-02-12 IL IL295149A patent/IL295149A/en unknown
- 2021-02-12 EP EP21754160.6A patent/EP4103165A4/en not_active Withdrawn
- 2021-02-12 CN CN202180013564.7A patent/CN115066235A/zh active Pending
- 2021-02-17 TW TW110105371A patent/TW202140026A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023514568A5 (https=) | ||
| US20210100813A1 (en) | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors | |
| JP6761852B2 (ja) | がん治療 | |
| CN103442710B (zh) | 检测点激酶1抑制剂和wee1激酶抑制剂的组合 | |
| TW201924720A (zh) | Ｐａｒｐ抑制劑用於治療化療耐藥的卵巢癌或乳腺癌的用途 | |
| CN112870367B (zh) | Ezh2抑制剂、cdk4/6抑制剂和mek抑制剂在制备治疗肿瘤药物中的用途 | |
| JP2021523189A (ja) | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物およびその使用方法 | |
| WO2018214925A1 (zh) | 用于治疗结直肠癌的喹啉衍生物 | |
| CN116270644A (zh) | Cdk9抑制剂与bcl-2抑制剂联用的药物组合及其用途 | |
| CN101107001A (zh) | 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂 | |
| CN120659606A (zh) | 治疗转移性去势抵抗性前列腺癌的他拉唑帕尼及恩杂鲁胺的组合 | |
| TW201625243A (zh) | 用於治療黑素瘤之藥物組合 | |
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| EP2754441B1 (en) | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives | |
| CN110840892A (zh) | 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途 | |
| JP2021063014A (ja) | 白血病治療薬 | |
| CN112870366A (zh) | Ezh2抑制剂在制备治疗肿瘤药物中的新用途 | |
| CN104271129A (zh) | 使用极光激酶抑制剂治疗癌症的方法 | |
| AU2004273605B2 (en) | Treatment of gastrointestinal stromal tumors with imatinib and midostaurin | |
| JP2023518132A (ja) | Ｃｔｂ００６とポナチニブとの併用の適用 | |
| JP2010523470A (ja) | 抗癌化合物の投与方法 | |
| JP6810763B2 (ja) | がん治療 | |
| KR20240139581A (ko) | 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형 | |
| WO2022184664A1 (en) | Anticancer combination therapy | |
| CN1649583A (zh) | 包括取代的丙烯酰偏端霉素衍生物和放射治疗的抗肿瘤联合疗法 |